These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 21885001

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology.
    Morgensztern D, Govindan R.
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S57-61. PubMed ID: 21885000
    [Abstract] [Full Text] [Related]

  • 8. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C.
    Clin Lung Cancer; 2008 Mar; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [Abstract] [Full Text] [Related]

  • 9. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
    Sandler AB, Johnson DH, Herbst RS.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
    [Abstract] [Full Text] [Related]

  • 10. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A, Van Cutsem E.
    Oncology; 2005 Jun 15; 69 Suppl 3():46-56. PubMed ID: 16301835
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
    Laskin J, Crinò L, Felip E, Franke F, Gorbunova V, Groen H, Jiang GL, Reck M, Schneider CP.
    J Thorac Oncol; 2012 Jan 15; 7(1):203-11. PubMed ID: 22173662
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, Pronzato P, Grossi F.
    Crit Rev Oncol Hematol; 2008 Dec 15; 68(3):183-96. PubMed ID: 18606548
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
    Kentepozidis N, Kotsakis A, Soultati A, Agelaki S, Christophylakis Ch, Agelidou M, Chelis L, Papakotoulas P, Vamvakas L, Zafiriou Z, Samonis G, Georgoulias V.
    Cancer Chemother Pharmacol; 2013 Mar 15; 71(3):605-12. PubMed ID: 23338050
    [Abstract] [Full Text] [Related]

  • 17. Bevacizumab for the treatment of advanced non-small-cell lung cancer.
    Manegold C.
    Expert Rev Anticancer Ther; 2008 May 15; 8(5):689-99. PubMed ID: 18471042
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Bevacizumab in the first-line therapy of advanced NSCLC].
    Hasenöhrl N.
    Wien Med Wochenschr; 2007 May 15; 157(21-22):576-8. PubMed ID: 18157597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.